Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
about
Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective studyBone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritisObesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Osteoporosis in the rheumatic disease patient.Cytokines in immunotherapy of experimental uveitis.Small molecule glutaminase inhibitors block glutamate release from stimulated microglia.Engineering mesenchymal stem cells for immunotherapy.The acute and sensitization effects of tumor necrosis factor-α: implications for immunotherapy as well as psychiatric and neurological conditions.Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms.Parasite excretory-secretory products and their effects on metabolic syndrome.Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brainSilencing TNF-α in macrophages and dendritic cells for arthritis treatment.Tumor necrosis factor-alpha-associated lysosomal permeabilization is cathepsin B dependent.Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade.Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner.
P2860
Q24798468-568516B2-1C01-46D3-B025-EA0F2B37397FQ24805600-8143C955-5354-46D7-BE92-021A3477A627Q33580624-8D3EBB3A-C199-4C13-B70F-E1B1AAA5A845Q33944344-384D1B13-4827-41EB-99BE-66E5F8189CCBQ34451956-A470FEF3-0912-498F-A13E-50370382EDC9Q34986976-6B1F627D-0282-4942-AD0C-940A75D9CBD1Q34993224-45DC8041-02C0-4AB4-B1EE-68CA43166BE0Q35051773-21809C8C-9978-46FD-A9A6-1D76C304981DQ35122181-06BFC2BF-8045-4D51-B01F-5AC4AA1A2C6DQ38777671-DFC36218-7C20-4355-82A4-FA5FED547A50Q38969134-08E99FAB-F5C7-42D8-8710-773E9B83DBC6Q39032609-57F291A5-D136-44EA-B18C-DCE977F8BB64Q39683541-B4953B48-E026-46AD-8152-94AEAD5439BEQ42266961-599906B8-F15E-4B6B-8725-E20ED6784E53Q44132425-C8613C2F-5B38-4EE9-A32B-3890FF6EA1E6Q44591644-B850DE25-36A0-4306-B28E-147EA25B1867Q53278044-5061C9F8-7124-4E45-8569-A1F9F8F66BBE
P2860
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@ast
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@en
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@nl
type
label
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@ast
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@en
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@nl
prefLabel
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@ast
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@en
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@nl
P1476
Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases.
@en
P2093
P304
P356
10.1016/S0952-7915(00)00167-9
P577
2000-12-01T00:00:00Z